Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)‘s stock had its “hold” rating restated by investment analysts at Cantor Fitzgerald in a report released on Friday. They presently have a $2.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential downside of 28.06% from the company’s current price.
The analysts wrote, “ARO-AAT and ARO-HBV in 1H18. Arrowhead’s lead preclinical programs are expected to have CTAs filed in 1Q18 and 2Q18, respectively. Gating items for these candidates include GLP toxicity studies (both candidates) and completion of cross reactivity studies for ARO-HBV. We are encouraged by the significant progress made and the established guidance to reach the clinic with two candidates by 1H18.””
Several other equities research analysts have also issued reports on ARWR. ValuEngine lowered Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reaffirmed a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $2.00.
Arrowhead Pharmaceuticals (ARWR) opened at 2.78 on Friday. Arrowhead Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $8.09. The firm has a 50-day moving average price of $2.37 and a 200 day moving average price of $1.88. The company’s market capitalization is $207.87 million.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The firm had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. On average, analysts predict that Arrowhead Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/cantor-fitzgerald-reaffirms-hold-rating-for-arrowhead-pharmaceuticals-inc-arwr.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. Baker BROS. Advisors LP bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $13,649,000. RA Capital Management LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $11,212,000. RTW Investments LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $8,208,000. Perceptive Advisors LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $1,313,000. Finally, Hillhouse Capital Management Ltd. bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $4,983,000. 20.63% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.